Topics

Mallinckrodt Sells BioVectra to H.I.G. Capital

02:56 EDT 13 Sep 2019 | CHEManager

Mallinckrodt has agreed to sell its wholly owned subsidiary BioVectra to an affiliate of private equity group H.I.G. Capital for $250 million. The price includes a fixed sum of $175 million, made up of an upfront payment of $135 million plus a long-term note for $40 million, as well as contingent payments of up to $75 million.

Original Article: Mallinckrodt Sells BioVectra to H.I.G. Capital

NEXT ARTICLE

More From BioPortfolio on "Mallinckrodt Sells BioVectra to H.I.G. Capital"

Quick Search